Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay
Tracy E
TE
University of Kentucky, Gill Heart Institute, Division of Cardiovascular Medicine, 900 South Limestone, 326 Wethington Building, Lexington, KY 40536-0200, USA.
Allen
Christopher
C
Ziada
Khaled M
KM
D000284:Administration, Oral; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D044463:Receptor, PAR-1 / Q000097:blood; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D044463:Receptor, PAR-1; C530299:vorapaxar